User profiles for Jinoos Yazdany

Jinoos Yazdany

UCSF
Verified email at ucsf.edu
Cited by 17441

Potential biases in machine learning algorithms using electronic health record data

MA Gianfrancesco, S Tamang, J Yazdany… - JAMA internal …, 2018 - jamanetwork.com
A promise of machine learning in health care is the avoidance of biases in diagnosis and
treatment; a computer algorithm could objectively synthesize and interpret the data in the …

A quality indicator set for systemic lupus erythematosus

J Yazdany, P Panopalis, JZ Gillis… - Arthritis Care & …, 2009 - Wiley Online Library
Jinoos YazdanyJinoos YazdanyYazdany had full access to all of the data in the study
and takes responsibility for the integrity of the data and the accuracy of the data analysis. …

[PDF][PDF] Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice

J Anderson, L Caplan, J Yazdany… - Arthritis care & …, 2012 - Wiley Online Library
Objective Although the systematic measurement of disease activity facilitates clinical
decision making in rheumatoid arthritis (RA), no recommendations currently exist on which …

Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know

J Yazdany, AHJ Kim - Annals of internal medicine, 2020 - acpjournals.org
Two medications often used for treatment of immune-mediated conditions, hydroxychloroquine
and chloroquine, have recently attracted widespread interest as potential therapies for …

Single-cell RNA-seq reveals cell type–specific molecular and genetic associations to lupus

…, L Fong, M Dall'Era, B Balliu, A Regev, J Yazdany… - Science, 2022 - science.org
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. Knowledge
of circulating immune cell types and states associated with SLE remains incomplete. We …

[HTML][HTML] COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

R Grainger, AHJ Kim, R Conway, J Yazdany… - Nature Reviews …, 2022 - nature.com
The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

Assessment of a deep learning model based on electronic health record data to forecast clinical outcomes in patients with rheumatoid arthritis

…, B Oskotsky, G Schmajuk, J Yazdany… - JAMA network …, 2019 - jamanetwork.com
Importance Knowing the future condition of a patient would enable a physician to customize
current therapeutic options to prevent disease worsening, but predicting that future condition …

[HTML][HTML] Approaches for estimating minimal clinically important differences in systemic lupus erythematosus

SK Rai, J Yazdany, PR Fortin… - Arthritis research & …, 2015 - Springer
A minimal clinically important difference (MCID) is an important concept used to determine
whether a medical intervention improves perceived outcomes in patients. Prior to the …

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

…, JT Merrill, DJ Wallace, J Yazdany… - Arthritis care & …, 2012 - Wiley Online Library
In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60% …

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician …

…, E Sirotich, P Sufka, ZS Wallace, J Yazdany… - Annals of the …, 2020 - ard.bmj.com
Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood.
The aim was to examine demographic and clinical factors associated with COVID-19 …